Kodu・Aktsiate loetelu・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Suletud

10.01 -2.25

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.76

Max

10.05

Põhinäitajad
By Trading Economics
Sissetulek	-4.3M -18M
Aktsiakasum	-0.19
Töötajad	37
EBITDA	-5.3M -17M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+186.64% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. nov 2026

Turustatistika
By TradingEconomics
Turukapital	-245M 879M
Eelmine avamishind	12.26
Eelmine sulgemishind	10.01

Corvus Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. okt 2026, 23:56 UTC

Scholar Rock Holding Corporation's shares are trading modestly lower in after-market hours, retracing from an early peak following a brief uptick after Friday's close.

30. okt 2026, 23:56 UTC

Surgery Partners, Inc. is trading modestly lower in after-market hours, settling at its lowest point despite a brief recovery earlier in the session.

30. okt 2026, 23:56 UTC

Aquestive Therapeutics, Inc. is trading modestly higher in after-market hours following a notable increase after an initial dip earlier in the session.

30. okt 2026, 23:56 UTC

Patterson-UTI Energy Inc shares traded modestly lower in after-market hours, retracing some gains after a brief improvement following Friday's close.

30. okt 2026, 23:56 UTC

Avantor, Inc. shares are declining in after-market trading, continuing a downward trend since Friday's close and reaching their lowest point late in the session.

30. okt 2026, 23:56 UTC

Xometry, Inc. is trading modestly higher in after-market hours, reaching a peak since Friday's close despite an initial dip.

30. okt 2026, 23:56 UTC

Social Media

Take-Two Interactive Software, Inc. shares are trading modestly higher in after-market hours.

30. okt 2026, 23:56 UTC

Krispy Kreme, Inc. shares are trading modestly lower in after-market hours, following a recent decline.

30. okt 2026, 23:56 UTC

LyondellBasell Industries N.V. is trading lower in after-market hours, with a cumulative return decrease from a low of -1.30% to -0.58% since Friday's close.

30. okt 2026, 23:56 UTC

Canadian Solar Inc. is trading modestly lower in after-market hours, following a slight recovery from an earlier decline at the market close.

30. okt 2026, 23:56 UTC

The Nikkei 225 Index declined during after-market hours, continuing a downward trend amid broader market weakness and slowing business activity indicated by Chicago PMI data.

30. okt 2026, 23:56 UTC

ConocoPhillips shares are trading lower in after-market hours, having retraced from an earlier peak and remaining down since Friday's close.

30. okt 2026, 23:56 UTC

Pool Corporation shares traded modestly lower in after-market hours, continuing a decline that began after Friday's close.

30. okt 2026, 23:56 UTC

Wingstop Inc. is trading lower in after-market hours, having earlier dipped as much as 1.51% from Friday's close.

30. okt 2026, 23:56 UTC

Fastenal Company shares are trading modestly higher in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

30. okt 2026, 23:56 UTC

AAON, Inc. shares are modestly higher in after-market trading, recovering from recent weakness.

30. okt 2026, 23:52 UTC

Australia's Balance of Trade report on November 5 expected to show AUD 1 billion surplus, reflecting strong resource exports and positive market sentiment.

30. okt 2026, 23:52 UTC

Brazil's Industrial Production MoM data release on November 5, 2026, raises cautious market expectations amid ongoing declines and economic challenges.

30. okt 2026, 23:51 UTC

Champion Homes Inc. is trading modestly lower in after-market hours, having retraced from a brief peak earlier in the session.

30. okt 2026, 23:51 UTC

Sarepta Therapeutics, Inc. is trading modestly higher in after-market hours after a strong upward movement from a low point shortly after the market closed.

30. okt 2026, 23:51 UTC

Social Media

In after-market hours, Lowe's shares traded lower, retracing from earlier gains to below Friday's close, despite discussions on its dividend performance.

30. okt 2026, 23:51 UTC

Herc Holdings Inc. is trading lower in after-market hours, reversing an earlier uptick and declining since Friday's close.

30. okt 2026, 23:51 UTC

Cabaletta Bio, Inc. shares declined in after-market trading after a volatile session, currently positioned below its 20-day moving average and near the month's lower range.

30. okt 2026, 23:51 UTC

The New York Times Company is trading higher in after-market hours, reaching a high above its 20-day moving average and near the upper end of its one-month range.

30. okt 2026, 23:51 UTC

W. P. Carey Inc. has advanced modestly in after-market trading, reaching a high point near the upper end of its one-month trading range.

30. okt 2026, 23:51 UTC

Axsome Therapeutics, Inc. is advancing in after-market trading.

30. okt 2026, 23:51 UTC

News

FMC Corp shares are declining in after-market hours following disappointing Q3 earnings, with an 80% revenue drop to $106 million and an adjusted loss per share of $4.41.

30. okt 2026, 23:51 UTC

News

BTIG suspended its Buy rating on Zoetis Inc, contributing to a modest decline in the stock during after-market hours.

30. okt 2026, 23:51 UTC

Goodyear Tire & Rubber Co is trading modestly higher in after-market hours, recovering from earlier fluctuations during the session.

30. okt 2026, 23:51 UTC

News

Stryker receives mixed analyst assessments, with Stifel lowering its price target to $325 and Citigroup adjusting to $315, both maintaining Buy ratings.

Võrdlus sarnastega

Hinnamuutus

Corvus Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

186.64% tõus

12 kuu keskmine prognoos

Keskmine 28.75 USD 186.64%

Kõrge 33 USD

Madal 27 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Corvus Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Corvus Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.